Dr. Reddy’s launches generic Zyban
Dr. Reddy’s is debuting bupropion hydrochloride extended-release tablets.
The product is the generic of GlaxoSmithKline’s Zyban (bupropion hydrochloride) extended-release tablets.
The Zyban brand and generic had a market value of approximately $5.4 million for the most recent 12 months, ended June 2019, according to IQVIA.
Dr. Reddy’s bupropion hydrochloride extended-release tablets are available in a strength of 150 mg, in 60-count bottles.
The product is the generic of GlaxoSmithKline’s Zyban (bupropion hydrochloride) extended-release tablets.
The Zyban brand and generic had a market value of approximately $5.4 million for the most recent 12 months, ended June 2019, according to IQVIA.
Dr. Reddy’s bupropion hydrochloride extended-release tablets are available in a strength of 150 mg, in 60-count bottles.